Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...
Zacks Small Cap Research on MSN
ACHV: FDA’s CNPV Awarded for Vaping
ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter results, wrapping up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback